The digital subscription version of the Immunotherapy for Squamous Cell Carcinoma of the Head and Neck GUIDELINES Pocket Guide contains all the same great information found in the physical pocket guide, and can be accessed on mobile devices and online:
Price: $4.99 per year
Subscribe to additional guideline titles for discounted rates
Includes automatic updates during the term of your subscription
CPT® and ICD10 codes can be added to certain guidelines for an additional fee
Supported platforms
iPhone and iPad
Android phones and tablets
Online (internet connection required)
Content on the Guideline Central mobile app accessible without an internet connection
Access to additional guideline summaries, clinical calculators, and more
For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.
For individual use only; contact us for group and site licenses.
The Squamous Cell Carcinoma of the Head and Neck Pocket Guide is endorsed by the Society for Immunotherapy of Cancer and based on the latest SITC guidelines. This practical quick-reference tool contains a table of graded key recommendations and a management algorithm for recurrent and metastatic disease.
Multi-Fold
8 Pages
80# Diamond Silk Cover with Satin Aqueous Coating
4.25″ x 7.25″
Key Points
Tables
Key clinical immunotherapy recommendations for treatment of patients with HNC
Figures
First-line Treatment Algorithm for R/M HNSCC Patients
The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
Squamous cell carcinoma of the head and neck (HNSCC) is the 9th leading cancer by incidence worldwide and constitutes 90% of all head and neck cancers.
HNSCC is a biologically diverse and genomically heterogeneous disease that arises from the squamous mucosal lining of the upper aerodigestive tract.
In addition to traditional risk factors including smoking and alcohol consumption, over the last two to three decades it has become apparent that the human papillomavirus (HPV) and Epstein Barr Virus (EBV) are associated with development of squamous cell carcinoma of the oropharynx and nasopharynx, respectively.
Despite advances in surgery and radiotherapy, five-year survival rates for patients (excluding EBV-related nasopharyngeal) with HNSCC across all stages remain 40-50% for tumors caused by the traditional carcinogens smoking and alcohol consumption.
Between 2016 and 2019, the US Food and Drug Administration (FDA) approved two immunotherapeutic agents, the anti-programmed cell death protein (PD-1) monoclonal antibodies, nivolumab (Opdivo, Bristol-Myers Squibb) and pembrolizumab (Keytruda, Merck), for the treatment of patients with recurrent/metastatic (R/M) HNSCC.
Anti-PD-1/PD-L1 ICIs can block suppressive signaling of T cell immunological responses through the PD-1/PD-L1 pathway and enhance antitumor immune activity.
Want to save this for later? And your free sample to your Library.
Add to Library
Related Pocketcards
To get started, log in or create your free account Create Account
Our Commitment to Our Customer’s Privacy
Thank you for being a user of Guideline Central!
As part of our continued efforts towards protecting your privacy and personal information, we’ve made recent updates to our privacy policy.
By updating our privacy policy with clearer language, our goal is to help you better understand what data we collect and how we use that information.
When we collect your data through site visits and account creation, we agree to never sell that information to third-parties.
This personal information is used solely to provide you a more personalized experience when using the Guideline Central website and app.
At any time, you may opt out of tracking or request account deletion.
Please visit our privacy policy page for more information.
